COAPTITE Agent, Bulking, Injectable For Gastro-Urology Use
Merz North America, Inc. · Decision date Jun 26, 2026
What did the FDA decide?
FDA records P040047/S083 as a supplement to PMA P040047, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jun 26, 2026.
FDA approval order statement
modification of the Dynamic Crossflow Filtration (DCF) System for use in calcium hydroxylapatite (CaHA) particle manufacturing for the Radiesse, Radiesse (+), and Coaptite product lines.
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Jun 26, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P040047/S083
- Regulatory pathway
- PMA supplement
- Applicant
- Merz North America, Inc.
- Product code
- LNM
- Decision code
- OK30
- Decision date
- Jun 26, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: AGENT, BULKING, INJECTABLE FOR GASTRO-UROLOGY USE.
- Applicant
- Merz North America, Inc.
- Product code
- LNM
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P040047/S078 · Related supplement
COAPTITE Injectable Implant
P040047/S081 · Related supplement
COAPTITE Injectable Implant
P040047/S082 · Related supplement
COAPTITE AGENT, BULKING, INJECTABLE FOR GASTRO-UROLOGY USE
P040047/S083 received
Application receipt date recorded by FDA.
P040047/S083 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P040047. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P040047
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
COAPTITE Injectable ImplantP040047/S078 | Merz North America, Inc. | PMA supplement | Aug 27, 2025 | FDA |
COAPTITEP040047/S079 | Merz North America, Inc. | PMA supplement | Dec 12, 2025 | FDA |
COAPTITEP040047/S080 | Merz North America, Inc. | PMA supplement | Jan 13, 2026 | FDA |
COAPTITE Injectable ImplantP040047/S081 | Merz North America, Inc. | PMA supplement | Mar 18, 2026 | FDA |
| Merz North America, Inc. | PMA supplement | May 14, 2026 | FDA |
Explore the linked device profile
Other records with product code LNM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Bulkamid Urethral Bulking SystemP170023/S024 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Jul 1, 2026 | FDA |
Durasphere Injectable Bulking AgentP980053/S021 | Carbon Medical Technologies, Inc. | PMA supplement | Mar 13, 2026 | FDA |
Bulkamid Urethral Bulking SystemP170023/S023 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Jan 2, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Merz North America, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 4133 Ct.Ney Rd., Suite 10, Franksville, WI, 53126
Sources and methodology
- Original FDA record: P040047/S083
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

